Given the first time description of hGH-V detection in the GTD
patient's serum, we aimed to determine its possible role as a biomarker
for monitoring surgical or medical treatment.
With the availability of accurate and sensitive tests for the detection
of hCG and the use of early transvaginal ultrasonographic examination
the historically significant morbidity and mortality of GTD were drastically
reduced.